An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib)
Activo, no reclutaFase 4ClinicalTrials.gov
ID: NCT03975829Tipo: INTERVENTIONALInicio: 4 de nov de 2019Fin estimado: 6 de nov de 2026
A roll-over study to assess long-term effect in pediatric patients treated with dabrafenib and/or trametinib.
Elegibilidad
Edad mínima: 1 YearEdad máxima: 99 YearsSexo: ALL
Criterios de inclusión
All Subjects:
Written informed consent, according to local guidelines, signed by the subjects and/or by the parents or legal guardian prior to any study related screening procedures are performed.
Participation in a Novartis sponsored study such as CTMT212X2101, CDRB436G2201, CDRB436A2102, regardless of current age.
Parent study (or cohort of parent study) is planned to be closed.
Subject has demonstrated compliance, as assessed by the investigator, within the parent study protocol requirement(s).
Willingness and ability to comply with scheduled visits, treatment plans and any other study procedures.
For Subjects Entering the Treatment Period:
Subject is currently receiving treatment with dabrafenib/trametinib monotherapy or combination within a Novartis Sponsored Drug Development study. Note that subjects who were on the chemotherapy arm of the CDRB436G2201 study are eligible for treatment period of this study only after crossing over into the experimental treatment arm of the CDRB436G2201 study
In the opinion of the investigator is likely to benefit from continued treatment.
Criterios de exclusión
All Subjects:
For Subjects Entering the Treatment Period:
\- Subject has participated in a combination trial where dabrafenib and/or trametinib was dispensed in combination with another study medication.
Subject has permanently discontinued from study treatment in the parent protocol due to any reason.
Treatment with dabrafenib and/or trametinib for the subject's indication is approved for marketing and the appropriate dosage form is commercially available and reimbursed in the local country
Subject currently has unresolved drug related severe toxicities for which dabrafenib and/or trametinib dosing has been interrupted in the parent study. If the subject should meet criteria to resume treatment on the parent protocol then they may be eligible for treatment in this study.
Other protocol-defined inclusion/exclusion may apply.
Intervenciones
drug
dabrafenib
dabrafenib oral, twice daily
drug
trametinib
trametinib oral, once daily
Ubicaciones
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Patrocinadores
PrincipalNovartis Pharmaceuticals
Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.
An Open Label, Multi-center Roll-over Study to Assess Lon... | EligiMed